Peptide Companion
Back to catalog
Peptide Companion
single
Weight Management
Vial: 5 mg

AOD-9604 (5 mg Vial)

AOD-9604 dosage protocols leverage this synthetic 16‑amino‑acid fragment (Tyr‑hGH 177–191) to support lipolysis (fat breakdown) and inhibit lipogenesis (fat storage) without elevating IGF‑1 levels or causing insulin resistance. Clinical trials have demonstrated that AOD‑9604 exhibits a placebo‑like safety profile in obese adults, making it a well‑tolerated option for metabolic support. This educational protocol outlines a once‑daily subcutaneous approach using a practical dilution for clear insulin‑syringe measurements.

Dose
0.3–0.6 mg per injection
Frequency
Once daily
Timing
Morning, fasted
Duration
12+ weeks

HGH fragment (176-191). Targets fat metabolism without affecting blood sugar. Best results with fasted cardio.

Dosing Schedule
WeekDaily Dose (mcg)Units (per injection) (mL)
Weeks 1–4300 mcg18 units (0.18 mL)
Weeks 5–12500 mcg30 units (0.30 mL)
Supplies Needed
  • •Peptide Vials (AOD-9604, 5 mg each):
  • •Insulin Syringes (U‑100):
  • •Bacteriostatic Water (10 mL bottles): Use 3.0 mL per vial for reconstitution.
  • •Alcohol Swabs: One for the vial stopper + one for the injection site each day.
References

  • Journal of Endocrinology and Metabolism (2014)

    Safety and metabolism of AOD9604 as a nutraceutical ingredient; mechanism of action and metabolic studies

    View source

  • Journal of Endocrinology and Metabolism (2013)

    Safety and tolerability of AOD9604 in humans; no IGF‑1 increase; placebo‑like safety profile

    View source

  • FDA Pharmacy Compounding Advisory Committee (2024)

    AOD‑9604 bulk drug substance meeting memorandum; regulatory and safety overview

    View source

  • Endocrinology (OUP)

    Effects of hGH and AOD9604 on lipid metabolism in obese mice; β‑adrenergic pathway mechanisms

    View source

  • Bachem Peptide Guide

    Handling and storage guidelines for peptides; lyophilized stability recommendations

    View source

  • Creative Peptides

    Peptide stability and shelf life; reconstituted solution storage guidelines

    View source

  • MedlinePlus Medical Encyclopedia (NIH)

    Subcutaneous injection patient instructions; technique and site guidance

    View source

  • Olympia Pharmacy

    How to administer a subcutaneous injection; site rotation and hygiene

    View source

  • Endocrinology (OUP)

    Chronic AOD9604 treatment in obese and β3‑AR knockout mice; receptor upregulation

    View source

  • Gastroenterology

    Drug treatment of the overweight patient; AOD‑9604 RCT summary and clinical efficacy

    View source

  • Annals of Clinical and Laboratory Science (PubMed)

    Effect of intra‑articular AOD9604 with hyaluronic acid in rabbit osteoarthritis model

    View source

  • DrugBank

    AOD9604 drug summary; mechanism of action, bone and metabolic effects

    View source

  • CDC

    Vaccine administration: subcutaneous route; no aspiration required

    View source

Educational content adapted from peptidedosages.com. Not medical advice.